Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Boer, S.M. de"'
Autor:
Vermij, L., Jobsen, J.J., Leon-Castillo, A., Brinkhuis, M., Roothaan, S., Powell, M.E., Boer, S.M. de, Khaw, P., Mileshkin, L.R., Fyles, A., Leary, A., Genestie, C., Jnrgenliemk-Schulz, I.M., Crosbie, E.J., Mackay, H.J., Nijman, H.W., Nout, R.A., Smit, V.T.H.B.M., Creutzberg, C.L., Horeweg, N., Bosse, T., TransPORTEC Consortium
Publikováno v:
Vermij, L, Jobsen, J J, León-Castillo, A, Brinkhuis, M, Roothaan, S, Powell, M E, De boer, S M, Khaw, P, Mileshkin, L R, Fyles, A, Leary, A, Genestie, C, Jürgenliemk-Schulz, I M, Crosbie, E J, Mackay, H J, Nijman, H W, Nout, R A, Smit, V T H B M, Creutzberg, C L, Horeweg, N, Bosse, T & De boer, S M 2023, ' Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry ', British Journal of Cancer . https://doi.org/10.1038/s41416-023-02141-0
Background Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement. Methods Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bad7b755656c5121f11cc6c3a4a7c4f
https://hdl.handle.net/1887/3630351
https://hdl.handle.net/1887/3630351
Autor:
Bosse, T., Creutzberg, C.L., Crosbie, E.J., Han, K., Horeweg, N., Leary, A., Kroep, J.R., McAlpine, J.N., Powell, M.E., Blanc-Durand, F., Bruyn, M. de, Church, D.N., Koelzer, V.H., Kommoss, S., Singh, N., Bardet, A., Counsell, N., Putter, H., Tu, D., Edmondson, R., Gordon, C., Ledermann, J., Morice, P., MacKay, H., Nijman, H., Nout, R.A., Smit, V.T.H.B.M., White, H., Alexandre, J., Boer, S.M. de, Boere, I., Cooper, R., Ethier, J.L., Frenel, J.S., McGrane, J., Taylor, A., Welch, S., Westermann, A.M., Linden, H.D. van der, Farrelly, L., Feeney, A., Kaya, M., Liu, W., Melis, A., Ngadjeua-Tchouatieu, F., Parulekar, W., Verhoeven-Adema, K., RAINBO Res Consortium
Publikováno v:
International Journal of Gynecological Cancer, 33(1), 109-117. BMJ PUBLISHING GROUP
BackgroundThe endometrial cancer molecular classification has been integrated into the 2020 World Health Organization (WHO) diagnostic classification and European treatment guidelines, and provides direction towards more effective and less toxic adju
Autor:
Bomhof-Roordink, H., Stiggelbout, A.M., Gartner, F.R., Portielje, J.E.A., Kroon, C.D. de, Peeters, K.C.M.J., Neelis, K.J., Dekker, J.W.T., Weijden, T. van der, Pieterse, A.H., Boer, S.M. de, Boersma, L.J., Huinink, D.T., Buijsen, J., Cloos-van Balen, M., Gelderblom, H., Leeuwen-Snoeks, L. van, Lips, I.M., Ramai, S.R.S., Roshani, H., Slingerland, M., Vanneste, B.G.L., Wiltink, L.M., iSHARE Study Grp
Publikováno v:
Patient Education and Counseling, 105(5), 1089-1100. Elsevier Ireland Ltd
Patient Education and Counseling, 105(5), 1089-1100. ELSEVIER IRELAND LTD
Patient Education and Counseling, 105(5), 1089-1100. ELSEVIER IRELAND LTD
Objectives: We have developed two Dutch questionnaires to assess the shared decision-making (SDM) process in oncology; the iSHAREpatient and iSHAREphysician. In this study, we aimed to determine: scores, construct validity, test-retest agreement (iSH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::912883ab9c78f09a164110dc95c96878
https://hdl.handle.net/1887/3515773
https://hdl.handle.net/1887/3515773
Autor:
Boer, S.M. de
Publikováno v:
None
Approximately 15–20% of women with endometrial cancer have high-risk disease features and are at increased risk of distant metastases. Standard treatment after surgery is pelvic radiotherapy to reduce the risk of recurrence. In the international PO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::352d38931d1a1adb58dd98af0c73d2f4
https://hdl.handle.net/1887/80330
https://hdl.handle.net/1887/80330
Autor:
Boer, S.M. de, Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P.B., Ledermann, J.A., Khaw, P., Colombo, A., Fyles, A., Baron, M.H., Jurgenliemk-Schulz, I.M., Kitchener, H.C., Nijman, H.W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D., Hanzen, C., Lutgens, L.C.H.W., Smit, V.T.H.B.M., Singh, N., V. do, D'Amico, R., Nout, R.A., Feeney, A., Verhoeven-Adema, K.W., Putter, H., Creutzberg, C.L., PORTEC Study Grp
Publikováno v:
Lancet Oncology, 19(3), 295-309. ELSEVIER SCIENCE INC
The Lancet Oncology, 19(3), 295-309
Lancet Oncology, 19, 3, pp. 295-309
Lancet oncology, 19(3), 295-309. Elsevier Science
Lancet Oncology, 19, 295-309
The Lancet Oncology, 19(3), 295-309
Lancet Oncology, 19, 3, pp. 295-309
Lancet oncology, 19(3), 295-309. Elsevier Science
Lancet Oncology, 19, 295-309
Background Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy d
Autor:
Wortman, B.G., Creutzberg, C.L., Putter, H., Jurgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, L.C.H.W., Steen-Banasik, E.M. van der, Mens, J.W.M., Slot, A., Kroese, M.C.S., Triest, B. van, Nijman, H.W., Stelloo, E., Bosse, T., Boer, S.M. de, Putten, W.L.J. van, Smit, V.T.H.B.M., Nout, R.A., PORTEC Study Grp
Publikováno v:
British Journal of Cancer, 119(9), 1067-1074
British Journal of Cancer
British Journal of Cancer, 119(9), 1067-1074. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 119(9), 1067-1074. Nature Publishing Group
BACKGROUND: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal brachytherapy (VBT). We evaluated long-term outcomes combined with the results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4323ee51d7efa4e63c525cf8f65e972
https://hdl.handle.net/1887/86376
https://hdl.handle.net/1887/86376
Autor:
Boer, S.M. de, Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P.B., Ledermann, J.A., Khaw, P., Colombo, A., Fyles, A., Baron, M.H., Kitchener, H.C., Nijman, H.W., Kruitwagen, R.F., Nout, R.A., Verhoeven-Adema, K.W., Smit, V.T., Putter, H., Creutzberg, C.L., PORTEC Study Grp
Publikováno v:
Lancet oncology, 17(8), 1114-1126. Elsevier Science
The Lancet. Oncology
Lancet Oncology, 17, 8, pp. 1114-26
Lancet Oncology, 17(8), 1114-1126. ELSEVIER SCIENCE INC
The Lancet Oncology, 17(8), 1114-1126
Lancet Oncology, 17, 1114-26
The Lancet. Oncology
Lancet Oncology, 17, 8, pp. 1114-26
Lancet Oncology, 17(8), 1114-1126. ELSEVIER SCIENCE INC
The Lancet Oncology, 17(8), 1114-1126
Lancet Oncology, 17, 1114-26
Contains fulltext : 171831.pdf (Publisher’s version ) (Open Access) BACKGROUND: About 15% of patients with endometrial cancer have high-risk features and are at increased risk of distant metastases and endometrial cancer-related death. We designed
Publikováno v:
The Lancet Oncology, 19(5), 602-602
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f4d332b3882d2930312d35586e2f2631
https://hdl.handle.net/1887/118102
https://hdl.handle.net/1887/118102
Autor:
Boer, S.M. de, Wortman, B.G., Bosse, T., Powell, M.E., Singh, N., Hollema, H., Wilson, G., Chowdhury, M.N., Mileshkin, L., Pyman, J., Katsaros, D., Carinelli, S., Fyles, A., McLachlin, C.M., Haie-Meder, C., Duvillard, P., Nout, R.A., Verhoeven-Adema, K.W., Putter, H., Creutzberg, C.L., Smit, V.T.H.B.M., PORTEC Study Grp
Publikováno v:
Annals of Oncology, 29(2), 424-430
Annals of Oncology, 424-430
STARTPAGE=424;ENDPAGE=430;TITLE=Annals of Oncology
Annals of Oncology
Annals of Oncology, 29(2), 424-430. Oxford University Press
Annals of Oncology, 424-430
STARTPAGE=424;ENDPAGE=430;TITLE=Annals of Oncology
Annals of Oncology
Annals of Oncology, 29(2), 424-430. Oxford University Press
Background: In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, foll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc18ba38471d07b4e3ce0f37c0d670c1
http://hdl.handle.net/1887/75048
http://hdl.handle.net/1887/75048
Autor:
Creutzberg, C.L., Boer, S.M. de, Putter, H., Powell, M., Mileshkin, L.R., Katsaros, D., Bessette, P., Haie-Meder, C., Ledermann, J.A., Ottevanger, P.B., Khaw, P., Colombo, A., Fyles, A.W., Baron, M.H., Nijman, H.W., Nout, R.A., Smit, V.T.H.B.M., Verhoeven-Adema, K., Kruitwagen, R.F.P.M., Kitchener, H.C.
Publikováno v:
Journal of Clinical Oncology, 33(15)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::88347b1bf6a5d1ad869dd420d2d38193
https://hdl.handle.net/1887/100248
https://hdl.handle.net/1887/100248